Rifampicin (Rifcap 300 mg Kapsül) and Ubrogepant: interaction and safety
This source-based reference is not a personal treatment recommendation. The relevance and management of an interaction depend on the exact products, route, dose and clinical situation.
Interaction mechanism
Strong CYP3A4 induction can substantially reduce ubrogepant exposure.
Clinical significance and safety
Rifampin can reduce ubrogepant exposure through strong CYP3A4 induction. The ubrogepant label advises avoiding strong inducers because loss of migraine-treatment efficacy is expected. A clinician should review an alternative instead of the patient increasing ubrogepant use.
Using this information
This is a source-based reference record, not a recommendation to combine, stop or change medicines. A missing interaction record does not establish safe use. A qualified healthcare professional should consider the exact products, doses, other medicines and individual health circumstances.